Ruthigen, Inc., a wholly-owned subsidiary of Oculus Innovative Sciences, Inc., has appointed Sameer Harish to the position of CFO.
Mr Harish has over 15 years of healthcare industry experience. Prior to joining Ruthigen, Mr Harish served as principal of Harish Life Science Advisors since 2011, an independent consulting firm he founded that provided financial, strategic and market research advisory services to life science companies.
From 2005 until 2011, he served as an equity research analyst covering medical devices and diagnostics sectors with Needham & Co, and then subsequently at ThinkEquity. From 2002 through 2005, Mr Harish worked as a research analyst at Symmetry Capital, a healthcare-focused hedge fund, where he guided investments in the medical device, biotechnology and specialty pharmaceutical companies. Mr Harish also held research and laboratory positions at Guidant (now part of Abbott Laboratories) and Synteni (acquired by Incyte Corporation).
"We welcome Sameer's leadership and experience," said Hoji Alimi, CEO and chairman of Ruthigen. "This is a key appointment to our executive team at an important time for Ruthigen. We are confident that Sameer's strategic thinking and analytical background make him the right person to help us prepare to take Ruthigen public and to drive the company toward success in the coming years as we look to unlock the full value of our drug assets."